XIMELAGATRAN: ACTUALIZACION SOBRE EL MECANISMO DE ACCION Y EL DESARROLLO CLINICO DEL PRIMER INHIBIDOR DIRECTO DE LA TROMBINA POR VIA ORAL
Columnista Experto de SIIC Sarich, Troy
en colaboración con
Stig Boström, PhD Professor. AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden Ulf Eriksson, PhD. AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden Michael Wolzt, MD Clinical Pharmacology, Allgemeines Krankenhaus Wien, Medical University of Vienna, Vienna, Austria Christer Mattsson, PhD. AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden
Fecha de aprobación: 30 de Junio, 2004
Primera edición en siicsalud:
18 de Marzo, 2005
Sección Artículos originales,
subsección
Expertos del Mundo,
página
http://www.siicsalud.com/des/des042/05310028.htm
Especialidad principal:
 Farmacología.
Especialidades relacionadas:
 Bioquímica, Cardiología, Diagnóstico por Laboratorio, Medicina Farmacéutica, Medicina Interna, Medicina Interna.
|
Boström SL, Hansson GF, Sarich TC, Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma
Thrombosis Research
Sarich TC, Johansson S, Schutzer KM, Wall U, Kessler E, Teng R, Eriksson UG. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol
Journal of Clinical Pharmacology
Schutzer KM, Wall U, Lonnerstedt C, Ohlsson L, Teng R, Sarich TC, Eriksson UG. Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation
Current Medical Research and Opinion
Wolzt M, Boström SL, Svensson M, Wahlander K, Grind M, Sarich TC. Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation
Pathophysiology of Haemostasis and Thrombosis
Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wahlander K, Gustafsson D, Badimon JJ. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis
Journal of Thrombosis and Haemostasis
Dr. Sarich, Troy
Dirección profesional:
AstraZeneca LP, C4C-123, PO Box 15437, 1800 Concord Pike, Wilmington, DE 19850-5437, USA
|
